Analytical Data
-
Gene name
ADA1
- Application
-
Alternative Names
ADA1；ADA1；Adenosine deaminase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00813
-
Expression Region
1-363aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MAQTPAFDKP KVELHVHLDG SIKPETILYY GRRRGIALPA NTAEGLLNVI GMDKPLTLPD FLAKFDYYMP AIAGCREAIK RIAYEFVEMK AKEGVVYVEV RYSPHLLANS KVEPIPWNQA EGDLTPDEVV ALVGQGLQEG ERDFGVKARS ILCCMRHQPN WSPKVVELCK KYQQQTVVAI DLAGDETIPG SSLLPGHVQA YQEAVKSGIH RTVHAGEVGS AEVVKEAVDI LKTERLGHGY HTLEDQALYN RLRQENMHFE ICPWSSYLTG AWKPDTEHAV IRLKNDQANY SLNTDDPLIF KSTLDTDYQM TKRDMGFTEE EFKRLNINAA KSSFLPEDEK RELLDLLYKA YGMPPSASAG QNL
-
Molecular Weight
43 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Adenosine deaminase 1 (ADA1) is an essential enzyme that plays a crucial role in purine metabolism by catalyzing the deamination of adenosine to inosine, thereby regulating adenosine levels in tissues. Dysregulation of ADA1 has been associated with various pathological conditions, including immune deficiencies, neurodegenerative diseases, and certain cancers, making it a significant target for therapeutic intervention. Researchers have been investigating recombinant ADA1 to better understand its structure-function relationships, regulatory mechanisms, and interactions with other biomolecules. With advancements in recombinant DNA technology, scientists are now able to produce high yields of ADA1 protein in various expression systems, facilitating detailed biochemical analysis and drug discovery efforts. Moreover, modifications of the ADA1 protein, such as glycosylation or fusion to therapeutic agents, may enhance its stability and efficacy as a potential therapeutic tool. Overall, the study of recombinant ADA1 is pivotal in unraveling its biological functions and developing novel therapies for diseases linked to adenosine metabolism disruption.
